Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVID-Aging: HCQ, Telmisartan, and Azithromycin in Elderly COVID-19 Patients
NCT04359953Phase 3Terminated
- Sponsor
- Strasbourg University Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hydroxychloroquine, telmisartan and azithromycin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Two-weeks survival rate at 14 days. Started Apr 2020; status: terminated.
02
Drugs
hydroxychloroquinetelmisartanazithromycin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04359953.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04359953.